Click Therapeutics
Click Therapeutics is a US firm that develops software to address unmet medical need in smoking cessation and chronic affective disorders.
As of July 2018, three of the company's programs — Clickotine, for smoking cessation; Clickadian, for insomnia; and ClickEMFT, for major depression — are in the efficacy trial phase.
In Summer 2018, Click Therapeutics receieved $17 million in investment from French pharma major Sanofi.
Latest Click Therapeutics News & Features
11 September 2020
4 January 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze